Indeed, the major unmet need for osteoporosis therapy is additional drugs that stimulate bone formation ... mass phenotype explained by increased anabolic activity,” says David Lacey, Senior ...

It therefore seems that inhibitors of GDS synthesis could have the potential to become a new class of anabolic drugs for osteoporosis.

New tools have been developed in order to facilitate both the diagnosis and management of bone metabolic diseases. They are useful to estimate the long-term risk of suffering a fracture and ...

Osteoporosis is a very common disease that affects both men and women and produces an important burden. Fracture prevention is the primary treatment goal for patients with osteoporosis. There are ...

Eladynos – which is only the second osteoporosis drug to reach UK patients in the ... hormone-related protein (PTHrP) and as an anabolic agent works similarly to romosozumab and teriparatide ...

NaQuinate is under clinical development by Haoma Medica and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate ...

One growth driver is the increasing adoption of expensive anabolic therapies ... In addition, low compliance with osteoporosis drugs due to disruptive therapy regimens and adverse side effects ...